Cyclacel Pharmaceuticals, Inc. (CYCC) NASDAQ

0.32

-0.0082(-2.48%)

Updated at July 01 12:14PM

Currency In USD

Cyclacel Pharmaceuticals, Inc.

Address

200 Connell Drive

Berkeley Heights, NJ 07922

United States of America

Phone

908 517 7330

Sector

Healthcare

Industry

Biotechnology

Employees

12

First IPO Date

March 16, 2004

Key Executives

NameTitlePayYear Born
Dr. Sing Ee WongChairman, Chief Executive Officer & President01981
Grace KimInvestor Relations Executive0N/A
Mr. Cu Seng KiuExecutive Director, Chief Financial Officer & Secretary01990
Ms. Gill ChristieDirector of Human Resources01957

Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.